New hope for kidney patients: drug aims to prevent relapse
NCT ID NCT07604311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a 15-month course of Nefecon can prevent proteinuria relapse in 288 adults with IgA nephropathy who have already achieved remission. Participants must have completed prior Nefecon therapy and have stable kidney function. The goal is to see if maintenance treatment can keep the disease under control and slow progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nefecon (a targeted corticosteroid)
What this could lead to
If successful, this could offer a maintenance therapy to keep IgA nephropathy in remission and delay kidney disease progression.
What could go wrong
This is a phase 4 trial, but it is not yet recruiting. The benefit is only for patients already in remission, and long-term steroid use carries risks like infection or metabolic effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••